Loading...
Thromboprophylaxis for women undergoing caesarean section.
Kennedy, C O'Dwyer, V O'Kelly, S Farah, N Kennelly, M Turner, M J
Kennedy, C
O'Dwyer, V
O'Kelly, S
Farah, N
Kennelly, M
Turner, M J
Advisors
Editors
Other Contributors
Date
2012-02
Date Submitted
Keywords
Other Subjects
Subject Mesh
Cesarean Section
Female
Fibrinolytic Agents
Guideline Adherence
Heparin, Low-Molecular-Weight
Humans
Prospective Studies
Venous Thrombosis
Female
Fibrinolytic Agents
Guideline Adherence
Heparin, Low-Molecular-Weight
Humans
Prospective Studies
Venous Thrombosis
Planned Date
Start Date
Collaborators
Principal Investigators
Files
Loading...
Article6404.pdf
Adobe PDF, 9.55 KB
Alternative Titles
Publisher
Abstract
Thromboprophylaxis for women undergoing caesarean section (CS) was introduced in the hospital in 1995. This study audited the use of tinzaparin prophylaxis in a nested cohort of women who screened negative for diabetes mellitus at 28 weeks gestation. All the women had their weight measured and BMI calculated at the first antenatal visit. Of the 284 women, 68 (24%) had a CS and all received tinzaparin. Of the 68, however, 94% received a dose lower than recommended. Compliance with prophylaxis was complete but compliance with the recommended dosage was suboptimal, which may result in venous thromboembolism after CS despite thromboprophylaxis.
Language
en
ISSN
0332-3102
eISSN
ISBN
DOI
PMID
22455243